253 related articles for article (PubMed ID: 27280470)
1. Recent Developments of Magnetic Nanoparticles for Theranostics of Brain Tumor.
Shevtsov M; Multhoff G
Curr Drug Metab; 2016; 17(8):737-744. PubMed ID: 27280470
[TBL] [Abstract][Full Text] [Related]
2. Targeted superparamagnetic iron oxide nanoparticles for early detection of cancer: Possibilities and challenges.
Bakhtiary Z; Saei AA; Hajipour MJ; Raoufi M; Vermesh O; Mahmoudi M
Nanomedicine; 2016 Feb; 12(2):287-307. PubMed ID: 26707817
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in superparamagnetic iron oxide nanoparticles (SPIONs) for in vitro and in vivo cancer nanotheranostics.
Kandasamy G; Maity D
Int J Pharm; 2015 Dec; 496(2):191-218. PubMed ID: 26520409
[TBL] [Abstract][Full Text] [Related]
4. Next-generation superparamagnetic iron oxide nanoparticles for cancer theranostics.
Li K; Nejadnik H; Daldrup-Link HE
Drug Discov Today; 2017 Sep; 22(9):1421-1429. PubMed ID: 28454771
[TBL] [Abstract][Full Text] [Related]
5. Magnetic nanoformulations for prostate cancer.
Chowdhury P; Roberts AM; Khan S; Hafeez BB; Chauhan SC; Jaggi M; Yallapu MM
Drug Discov Today; 2017 Aug; 22(8):1233-1241. PubMed ID: 28526660
[TBL] [Abstract][Full Text] [Related]
6. Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges.
Laurent S; Saei AA; Behzadi S; Panahifar A; Mahmoudi M
Expert Opin Drug Deliv; 2014 Sep; 11(9):1449-70. PubMed ID: 24870351
[TBL] [Abstract][Full Text] [Related]
7. Triple Therapy of HER2
Zolata H; Afarideh H; Davani FA
Cancer Biother Radiopharm; 2016 Nov; 31(9):324-329. PubMed ID: 27831759
[TBL] [Abstract][Full Text] [Related]
8. Preparation, Characterization, and In Vitro pH-sensitivity Evaluation of Superparamagnetic Iron Oxide Nanoparticle- Misonidazole pH-sensitive Liposomes.
Li B; Li B; He D; Feng C; Luo Z; He M
Curr Drug Deliv; 2019; 16(3):254-267. PubMed ID: 30426901
[TBL] [Abstract][Full Text] [Related]
9. Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma.
Saesoo S; Sathornsumetee S; Anekwiang P; Treetidnipa C; Thuwajit P; Bunthot S; Maneeprakorn W; Maurizi L; Hofmann H; Rungsardthong RU; Saengkrit N
Colloids Surf B Biointerfaces; 2018 Jan; 161():497-507. PubMed ID: 29128836
[TBL] [Abstract][Full Text] [Related]
10. Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors.
Iv M; Telischak N; Feng D; Holdsworth SJ; Yeom KW; Daldrup-Link HE
Nanomedicine (Lond); 2015; 10(6):993-1018. PubMed ID: 25867862
[TBL] [Abstract][Full Text] [Related]
11. Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy.
Zhu L; Zhou Z; Mao H; Yang L
Nanomedicine (Lond); 2017 Jan; 12(1):73-87. PubMed ID: 27876448
[TBL] [Abstract][Full Text] [Related]
12. Magnetic iron oxide nanoparticles for tumor-targeted therapy.
Chen B; Wu W; Wang X
Curr Cancer Drug Targets; 2011 Feb; 11(2):184-9. PubMed ID: 21158723
[TBL] [Abstract][Full Text] [Related]
13. Reduced astrocyte viability at physiological temperatures from magnetically activated iron oxide nanoparticles.
Schaub NJ; Rende D; Yuan Y; Gilbert RJ; Borca-Tasciuc DA
Chem Res Toxicol; 2014 Dec; 27(12):2023-35. PubMed ID: 25347722
[TBL] [Abstract][Full Text] [Related]
14. Theranostic nanoparticles enhance the response of glioblastomas to radiation.
Wu W; Klockow JL; Mohanty S; Ku KS; Aghighi M; Melemenidis S; Chen Z; Li K; Morais GR; Zhao N; Schlegel J; Graves EE; Rao J; Loadman PM; Falconer RA; Mukherjee S; Chin FT; Daldrup-Link HE
Nanotheranostics; 2019; 3(4):299-310. PubMed ID: 31723547
[TBL] [Abstract][Full Text] [Related]
15. Iron oxide nanoparticles for targeted cancer imaging and diagnostics.
Rosen JE; Chan L; Shieh DB; Gu FX
Nanomedicine; 2012 Apr; 8(3):275-90. PubMed ID: 21930108
[TBL] [Abstract][Full Text] [Related]
16. Iron Oxide Nanoparticles for Breast Cancer Theranostics.
Shakil MS; Hasan MA; Sarker SR
Curr Drug Metab; 2019; 20(6):446-456. PubMed ID: 30465497
[TBL] [Abstract][Full Text] [Related]
17. Efficient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles combining magnetic hyperthermia and anti-cancer drug delivery.
Kossatz S; Grandke J; Couleaud P; Latorre A; Aires A; Crosbie-Staunton K; Ludwig R; Dähring H; Ettelt V; Lazaro-Carrillo A; Calero M; Sader M; Courty J; Volkov Y; Prina-Mello A; Villanueva A; Somoza Á; Cortajarena AL; Miranda R; Hilger I
Breast Cancer Res; 2015 May; 17(1):66. PubMed ID: 25968050
[TBL] [Abstract][Full Text] [Related]
18. A New Pharmacokinetic Model Describing the Biodistribution of Intravenously and Intratumorally Administered Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in a GL261 Xenograft Glioblastoma Model.
Klapproth AP; Shevtsov M; Stangl S; Li WB; Multhoff G
Int J Nanomedicine; 2020; 15():4677-4689. PubMed ID: 32669844
[TBL] [Abstract][Full Text] [Related]
19. Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery.
Gao N; Bozeman EN; Qian W; Wang L; Chen H; Lipowska M; Staley CA; Wang YA; Mao H; Yang L
Theranostics; 2017; 7(6):1689-1704. PubMed ID: 28529645
[TBL] [Abstract][Full Text] [Related]
20. Superparamagnetic iron oxide nanoparticles conjugated with folic acid for dual target-specific drug delivery and MRI in cancer theranostics.
Huang Y; Mao K; Zhang B; Zhao Y
Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 1):763-771. PubMed ID: 27770953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
